Key result
In dogs with dilated cardiomyopathy, GLP-1-(9-36) mimicked GLP-1-(7-36) by significantly reducing LV end-diastolic pressure and increasing cardiac output (P<0.01).
Why the study?
Does GLP-1-(9-36) improve left ventricular function and myocardial glucose uptake in dogs with dilated cardiomyopathy compared to GLP-1-(7-36) and saline?
Does GLP-1-(9-36) improve left ventricular function and myocardial glucose uptake in dogs with dilated cardiomyopathy compared to GLP-1-(7-36) and saline?
p-value: p=<0.01
The GLP-1 metabolite GLP-1-(9-36) is an active peptide that mimics the effects of GLP-1-(7-36) in improving LV hemodynamics and myocardial glucose uptake in a canine model of dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
GLP-1-(9-36) shows activity in canine DCM; leaves open metabolite contribution to human HF therapy.
Nikolaidis et al. (2005) studied Dilated cardiomyopathy (n=28). GLP-1-(9-36) vs. GLP-1-(7-36) and saline was evaluated on Left ventricular function and transmyocardial substrate uptake (p=<0.01). In dogs with dilated cardiomyopathy, GLP-1-(9-36) mimicked GLP-1-(7-36) by significantly reducing LV end-diastolic pressure and increasing cardiac output (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: